Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 345.00 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
330.00 360.00 345.00 345.00 345.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.16 -6.95 -0.27 96
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 345.00 GBX

Arecor Therapeutics (AREC) Latest News

More Arecor Therapeutics News
Arecor Therapeutics Investors    Arecor Therapeutics Takeover Rumours

Arecor Therapeutics (AREC) Discussions and Chat

Arecor Therapeutics Forums and Chat

Date Time Title Posts

Add a New Thread

Arecor Therapeutics (AREC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Arecor Therapeutics trades in real-time

Arecor Therapeutics (AREC) Top Chat Posts

Arecor Therapeutics Daily Update: Arecor Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 345p.
Arecor Therapeutics Plc has a 4 week average price of 345p and a 12 week average price of 345p.
The 1 year high share price is 460p while the 1 year low share price is currently 226p.
There are currently 27,835,024 shares in issue and the average daily traded volume is 653 shares. The market capitalisation of Arecor Therapeutics Plc is £96,030,832.80.
jones1961: Thanks Jimbo, Did they discuss potential mkt size and share in the Q&A, and if everything goes to plan when the product may come to market?
alloa2003: I dont think any one brand/product would take all of the insulin market so there is space for similar products to take a good share. Also, Arecor is anything but a one trick pony.
alloa2003: This has huge long term potential and the steady as we go approach should avoid huge volatility in the share price.
stupidboypike: Good steady results. However, they have introduced a potential further delay with the milestone for AT282. In the December 2021 announcement they said:- "...expects to transfer the final formulation to Hikma in 1H 2022" In these results this has become:- "AT282, .... We remain confident in reaching the next license milestone in this programme within 2022." So H1 has become sometime in 2022. This doesn't detract from the overall good progress at Arecor, but does underline the need for patience with a share like this. Best regards SBP
stupidboypike: sn, I agree, in fact we can see what happened in September when some people did want to buy in quantity, the share price doubled in a very short period. I have a decent holding of Arecor, built up over many years ( I held from the formation of the company), and I don't intend selling any until the value has properly started to come out. That in my opinion is many times the current market cap. Best regards SBP
stupidboypike: alloa, thank goodness I think Arecor shares are relatively free from traders. I'm not expecting any surprises (good or bad) on 25th, it's not like their sales (or costs) will have suddenly changed from expectations. Next news we are expecting is progress on the Hikma deal sometime in H1 2022, then news on the AT247 trial which completes H2 2022. In my view this is not a share for traders, but long term serious investors. Best regards SBP
sharesoc: In case you missed our webinar with Arecor Therapeutics (AREC), the recording can be found on our YouTube channel: hTTps://
alloa2003: Nice progress:- ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company's extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278. Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. This recently granted US patent, the first within the Group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress." Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. Arecor's strategy is to generate a fortress of both narrow and broad interrelated IP rights that cover the features of these products. US11278624 is the first granted US patent within the Group's comprehensive insulin IP strategy.
sharesoc: We are hosting a webinar with Arecor Therapeutics plc (AREC) on 15 March 2022, which may be of interest to current shareholders or potential investors. Sarah Howell (Chief Executive Officer) will be presenting. You can register here: hTTps://
alloa2003: "Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has commenced the US Phase I clinical trial of Arecor's lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days." Should hopefully get the company and its treatment line back in the news again.
Arecor Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Arecor The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 10:34:59